159 related articles for article (PubMed ID: 22839723)
1. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin.
Kim YH; Demierre MF; Kim EJ; Lerner A; Rook AH; Duvic M; Robak T; Samtsov A; McCulloch W; Chen SC; Waksman J; Nichols J; Whittaker S
Leuk Lymphoma; 2013 Feb; 54(2):284-9. PubMed ID: 22839723
[TBL] [Abstract][Full Text] [Related]
2. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
Whittaker SJ; Demierre MF; Kim EJ; Rook AH; Lerner A; Duvic M; Scarisbrick J; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Kim YH
J Clin Oncol; 2010 Oct; 28(29):4485-91. PubMed ID: 20697094
[TBL] [Abstract][Full Text] [Related]
3. Romidepsin treatment for relapsed or refractory peripheral and cutaneous T-cell lymphoma: Real-life data from a national multicenter observational study.
Shimony S; Horowitz N; Ribakovsky E; Rozovski U; Avigdor A; Zloto K; Berger T; Avivi I; Perry C; Abadi U; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2019 Dec; 37(5):569-577. PubMed ID: 31674027
[TBL] [Abstract][Full Text] [Related]
4. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides.
Foss F; Duvic M; Lerner A; Waksman J; Whittaker S
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):637-643. PubMed ID: 27637428
[TBL] [Abstract][Full Text] [Related]
5. Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma.
Kim EJ; Kim YH; Rook AH; Lerner A; Duvic M; Reddy S; Robak T; Becker JC; Samtsov A; McCulloch W; Waksman J; Whittaker S
Leuk Lymphoma; 2015; 56(10):2847-54. PubMed ID: 25791237
[TBL] [Abstract][Full Text] [Related]
6. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.
Poligone B; Rubio-Gonzalez B; Querfeld C
Dermatol Ther; 2019 Mar; 32(2):e12804. PubMed ID: 30549384
[TBL] [Abstract][Full Text] [Related]
7. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma.
Lyseng-Williamson KA; Yang LP
Am J Clin Dermatol; 2012 Feb; 13(1):67-71. PubMed ID: 22066664
[TBL] [Abstract][Full Text] [Related]
8. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy.
Duvic M; Bates SE; Piekarz R; Eisch R; Kim YH; Lerner A; Robak T; Samtsov A; Becker JC; McCulloch W; Waksman J; Whittaker S
Leuk Lymphoma; 2018 Apr; 59(4):880-887. PubMed ID: 28853310
[TBL] [Abstract][Full Text] [Related]
9. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
Kim M; Thompson LA; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
[TBL] [Abstract][Full Text] [Related]
10. Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data.
Bates SE; Eisch R; Ling A; Rosing D; Turner M; Pittaluga S; Prince HM; Kirschbaum MH; Allen SL; Zain J; Geskin LJ; Joske D; Popplewell L; Cowen EW; Jaffe ES; Nichols J; Kennedy S; Steinberg SM; Liewehr DJ; Showe LC; Steakley C; Wright J; Fojo T; Litman T; Piekarz RL
Br J Haematol; 2015 Jul; 170(1):96-109. PubMed ID: 25891346
[TBL] [Abstract][Full Text] [Related]
11. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.
Coiffier B; Pro B; Prince HM; Foss F; Sokol L; Greenwood M; Caballero D; Morschhauser F; Wilhelm M; Pinter-Brown L; Padmanabhan Iyer S; Shustov A; Nielsen T; Nichols J; Wolfson J; Balser B; Horwitz S
J Hematol Oncol; 2014 Jan; 7():11. PubMed ID: 24456586
[TBL] [Abstract][Full Text] [Related]
12. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma.
Iyer SP; Foss FF
Oncologist; 2015 Sep; 20(9):1084-91. PubMed ID: 26099743
[TBL] [Abstract][Full Text] [Related]
13. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.
Piekarz RL; Frye R; Turner M; Wright JJ; Allen SL; Kirschbaum MH; Zain J; Prince HM; Leonard JP; Geskin LJ; Reeder C; Joske D; Figg WD; Gardner ER; Steinberg SM; Jaffe ES; Stetler-Stevenson M; Lade S; Fojo AT; Bates SE
J Clin Oncol; 2009 Nov; 27(32):5410-7. PubMed ID: 19826128
[TBL] [Abstract][Full Text] [Related]
14. Low-dose electron beam radiation and romidepsin therapy for symptomatic cutaneous T-cell lymphoma lesions.
Akilov OE; Grant C; Frye R; Bates S; Piekarz R; Geskin LJ
Br J Dermatol; 2012 Jul; 167(1):194-7. PubMed ID: 22372971
[TBL] [Abstract][Full Text] [Related]
15. Romidepsin: in the treatment of T-cell lymphoma.
Yang LP
Drugs; 2011 Jul; 71(11):1469-80. PubMed ID: 21812508
[TBL] [Abstract][Full Text] [Related]
16. Romidepsin for the treatment of cutaneous T-cell lymphoma.
Campas-Moya C
Drugs Today (Barc); 2009 Nov; 45(11):787-95. PubMed ID: 20126671
[TBL] [Abstract][Full Text] [Related]
17. Romidepsin for cutaneous T-cell lymphoma.
Prince HM; Dickinson M
Clin Cancer Res; 2012 Jul; 18(13):3509-15. PubMed ID: 22535155
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.
Piekarz RL; Frye R; Prince HM; Kirschbaum MH; Zain J; Allen SL; Jaffe ES; Ling A; Turner M; Peer CJ; Figg WD; Steinberg SM; Smith S; Joske D; Lewis I; Hutchins L; Craig M; Fojo AT; Wright JJ; Bates SE
Blood; 2011 Jun; 117(22):5827-34. PubMed ID: 21355097
[TBL] [Abstract][Full Text] [Related]
19. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; He K; Sridhara R; Abraham S; Booth BP; Verbois L; Morse DE; Jee JM; Pope S; Harapanhalli RS; Dagher R; Farrell A; Justice R; Pazdur R
Clin Cancer Res; 2007 Apr; 13(8):2318-22. PubMed ID: 17438089
[TBL] [Abstract][Full Text] [Related]
20. Durable Responses With Maintenance Dose-Sparing Regimens of Romidepsin in Cutaneous T-Cell Lymphoma.
Martinez-Escala ME; Kuzel TM; Kaplan JB; Petrich A; Nardone B; Rosen ST; Guitart J
JAMA Oncol; 2016 Jun; 2(6):790-3. PubMed ID: 27054291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
